Latest Antisense Therap Ltd (ATHJF) Headlines

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Antisense Therap Ltd (ATHJF) Headlines

Antisense Therapeutics Selected to Present at Biotech Showcase(TM) 2014
PR Newswire - Tue Jan 07, 4:49PM CST
Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to advise that it has been selected to present at the Biotech Showcase 2014 conference to be held January 13-15, 2014, at The Parc 55 Wyndham Hotel in San Francisco, CA. This is a significant opportunity for ANP to present to and engage with distinguished US-based investors, prospective partners, and key industry leaders, and in particular discuss the successful progress of the company's Phase II acromegaly trial for ATL1103.

Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial
PR Newswire - Mon Dec 23, 6:15AM CST
Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to advise that positive results have been achieved from the interim analysis of a subset of available data from its Phase II clinical trial of ATL1103 in patients with the growth disorder, acromegaly.

Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6d8jw/hematopoietic) has announced the addition of the "Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2013" report to their offering. 'Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation. Scope - A snapshot of the global therapeutic scenario for Hematopoietic Stem Cell Transplantation. - A review of the Hematopoietic Stem Cell Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hematopoietic Stem Cell Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Hospira, Inc. Athersys, Inc. GlaxoSmithKline plc BioLineRx, Ltd. Celldex Therapeutics, Inc. Antisense Therapeutics Limited Actinium Pharmaceuticals, Inc. Pharmalink AB Polyphor Ltd. Kiadis Pharma B.V. Bellicum Pharmaceuticals, Inc. TaiGen Biotechnology Co., Ltd. TikoMed AB For more information visit http://www.researchandmarkets.com/research/n6...atopoietic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ANP to present at and attend major US investment, partnering and industry conferences
PR Newswire - Wed Aug 28, 6:30AM CDT
Antisense Therapeutics Limited (ASX:ANP) is pleased to advise that its Chief Executive Officer and Managing Director, Mark Diamond has been invited to present at two major investment and partnering focused conferences in the US, and will also attend an industry seminar on orphan drugs and rare diseases as the Company steps up its planning on its drug ATL1103 for acromegaly.

Bio-Path Holdings' Liposomal Delivery Technology Achieves Major Milestone in Development of Antisense Therapeutics
Business Wire - Fri Aug 09, 8:30AM CDT
Bio-Path Holdings, Inc. (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that a scientific assay has confirmed that its lead product candidate BP-100-1.01 (Liposomal Grb-2) inhibits the disease-causing target protein in patients with blood cancers. The assay was applied to patient samples taken from Bio-Path's Phase I clinical trial which is evaluating Liposomal Grb-2 in blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). This discovery is a significant milestone in the development of Bio-Path's liposomal delivery technology and the specific data from this testing is planned to be reviewed at the Annual Society of Hematology (ASH) meeting in December by Jorge Cortes, M.D., Professor and Deputy Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center (MD Anderson Cancer Center).

Percheron Therapeutics Ltd (PERCF) Stock Research Links

PERCF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SureDone's Taska AI: Transforming Marketplace Listings

Updated Category News Views 3

Revolutionizing the E-Commerce Landscape Wake up and smell the innovation, folks! SureDone is rolling out Taska AI, a tool that's set to declutter the chaotic world of enterprise marketplace listings. It's no bed of roses for sellers out there, dealing with diverse channel demands and post-submission hiccups. Taska AI steps in as the seasoned handyman these sellers...

Continue Reading
GoLive Streamers: A Social Media Wild Card

Updated Category News Views 5

Stepping Boldly into the Livestreaming Arena There's a new kid in the chaotic neighborhood of social media, and it's called GoLive Streamers. Not just another aimless stroll down Content Highway, GoLive is weaving its own defining path by fostering genuine real-time interaction. Launched in April 2026, this plucky platform has quickly amassed a following of over 74,000...

Continue Reading
SACHEU Partners with AI to Harness Real Customer Insights

Updated Category News Views 3

Rethinking Beauty Industry's AI Obsession Here’s a breath of fresh air from the otherwise AI-obsessed beauty landscape: SACHEU, the brand that's been turning heads in cosmetics, decided to pair up with Limitless Labs. This partnership isn't about ceding control to machines but amplifying genuine human voices in their product development process. Yeah, it's a...

Continue Reading
Epiclay: Game Changer for Sculptors Debuts

Updated Category News Views 10

Epiclay™ Brings New Energy to Sculpting World Folks, if ever there was a time to break the mold, it’s now, and Ace of Clay’s got us covered with Epiclay™—a fresh take on polymer clay that’s turning heads in the sculpture circuit. Over four long years, Ace of Clay, a brand that's gathered a rather colorful following through captivating sculptures and detailed...

Continue Reading
Class Action Lawsuit Targets Lincoln Educational Services

Updated Category News Views 3

Legal Maneuver Against Lincoln Educational Services Here we go again—another day, another lawsuit. The recent flap with Lincoln Educational Services Corporation (NASDAQ: LINC) is as classic as any market rug pull. Stepping into the spotlight, Wolf Haldenstein Adler Freeman & Herz LLP—a courtroom icon since 1888—has announced a class action lawsuit against Lincoln....

Continue Reading
First Lady Steals NYSE Show, Investors Eye Stakes

Updated Category News Views 3

Something's Buzzing at the Big Board Walk over to Wall Street on September 23rd, and guess what you get? A lot more than just stock tickers blinking away. First Lady Melania Trump’s stealing the show at the New York Stock Exchange to kick off the inaugural IMPERIA Summit. She’s there to sound the opening bell and lead the charge in a summit that's focused on the...

Continue Reading
RunVermont Revamps City Marathon, Adds Half for 2027

Updated Category News Views 3

Straight outta Burlington, the M&T Bank Vermont City Marathon is giving its course a facelift and, get this, throwing a half marathon into the mix for 2027. It's about time they shook things up, considering how this race is supposed to be one of the most welcoming on the block. I mean, you're talking about a marathon that's practically been the crown jewel of Vermont's...

Continue Reading
Riverside Theatre Appoints Seasoned CFO for Growth Phase

Updated Category News Views 5

Change Is Afoot at Riverside Theatre Down in Vero Beach, amid the sun-drenched coziness of Florida’s Treasure Coast, something’s cooking that has nothing to do with sunshine: Riverside Theatre snagged itself a new Chief Financial Officer. As nonprofits go, this one’s not a backyard operation—it’s the largest independent professional theatre in the entire state....

Continue Reading
IWP and SHARE Forge New Path for Filmmaker Funding

Updated Category News Views 3

Revolutionizing Film Financing The film industry has always been a tough nut to crack. Imagine trying to keep your creative baby yours without surrendering the crown jewels of intellectual property. Well, now, the cavalry with a fresh game plan has arrived, and both investors and filmmakers might be ready for another round. This isn't the typical PR fairytale; it's...

Continue Reading
Greasezilla Expands Infrastructure with Ashland Facility

Updated Category News Views 3

Greasezilla is shaking up the world of waste management, folks. With municipal sewer systems clogged by fats, oils, and grease, Greasezilla's no-nonsense approach is a breath of fresh air. They've just fired up their new regional hub in Ashland, Virginia, taking another hefty step towards easing this burden on municipalities. This ain't small potatoes—this national...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights into the Emerging Commercial Vehicle Market Trends

Updated Category News Views 166

Signs of Recovery in the Commercial Vehicle Market The commercial vehicle market is experiencing a notable recovery. According to the latest analysis from Work Truck Solutions, new commercial vehicle sales are revitalizing the industry, leading to advantageous effects in the used vehicle sector. As inventory levels stabilize, the ecosystem is transitioning into a phase...

Continue Reading
Orion S.A. Projects 2024 Performance Amidst Market Challenges

Updated Category News Views 271

Orion S.A. Projects 2024 Performance Amidst Market Challenges Orion S.A. (NYSE: OEC), a prominent name in the specialty chemicals sector, has recently shared insights into its financial performance for the fiscal year ending December 31, 2024. This preliminary update indicates that the anticipated adjusted EBITDA for the year might fall slightly short of the expected...

Continue Reading
STRADVISION and AMD Showcase Advanced AI Driving Solutions

Updated Category News Views 192

Innovative AI Driving Solutions Unveiled at CES At CES 2026, a transformative showcase unfolded as STRADVISION, known for its cutting-edge AI-based vision perception technology, teamed up with AMD to demonstrate the SVNet MultiVision perception software. This dynamic partnership introduced the AMD Versal™ AI Edge Series Gen 2 adaptive system-on-chip (SoC), elevating the...

Continue Reading
David Brindley Takes Helm as New CEO of Bidpath

Updated Category News Views 235

David Brindley Takes the Helm as CEO of Bidpath Bidpath, a leading global provider of auction technology, has announced the exciting appointment of David Brindley as its new Chief Executive Officer. He succeeds the company’s Founder and Executive Chairman, Adam Alexander, marking a significant change for the organization. Brindley’s Path at Bidpath David Brindley...

Continue Reading
Clariane's 2025 Half-Year Results: Financial Strength Revealed

Updated Category News Views 285

Clariane's Financial Performance in the First Half of 2025 In the first half of 2025, Clariane has demonstrated a significant ability to strengthen its financial position, completing a major €1.5 billion plan six months ahead of schedule. This plan involved strategic disposals that generated €1 billion, achieving an impressive average multiple of around 14 times the...

Continue Reading